logo

FDA Calendar

Share
Company Name Bristol-Myers Squibb Co.
Drug Name Lisocabtagene maraleucel (BLA)
Event Name FDA decision on Lisocabtagene maraleucel for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies
Event Date 08/17/2020
Outcome Date
Outcome
Drug Status Priority review
Rival Drugs
Market Potential
Other Approvals
News
Return to FDA Calendar

>